The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...
If the number of recent drug approvals for atopic dermatitis (AD) is overwhelming, the future is unlikely to be any less ...
The FDA has approved Lilly’s Ebglyss (lebrikizumab-lbkz) for the treatment of moderate to severe atopic dermatitis in adults ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric patients aged 12 years and older who weigh at least 40kg with moderate to severe atopic dermatitis whose ...
Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...
Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback